A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients

Inclusion Criteria: 1. Hemodialysis-dependent for at least 2 months prior to screening. 2. Receiving hemodialysis at least 2 times per week 3. Receiving erythropoietin (EPO) therapy. 4. Hemoglobin (Hgb) ≥ 8.5 and \< 11.5 g/dL at screening. 5. Ferritin \>500 ng/mL and ≤ 2000 ng/mL at screening. 6. TSAT ≤ 50% at a minimum of one time point during the 90 days prior to baseline. Exclusion Criteria: 1. Known diagnosis of hemochromatosis, bone marrow malignancy, lymphatic malignancy or myelodysplastic syndrome. 2. History of dialysis AV fistula thrombosis within 2 months prior to screening, or 2 or more episodes of AV fistula thrombosis within 6 months prior to screening. 3. Liver disease/dysfunction (Child-Pugh score ≥ 6), prior liver transplant, heart failure (NYHA Class III or IV); gastrointestinal bleeding. 4. A positive Hepatitis B surface antigen test result. Patients with Hepatitis C Virus (HCV) infection may be included if all other liver function eligibility criteria are met. 5. ALT, AST or bilirubin ≥ 1.5x ULN within 4 weeks prior to baseline. 6. Uncontrolled renal osteodystrophy 7. Conditions predisposing to an increased risk of serious infection, such as an indwelling vascular catheter (central venous line or non-tunneled/acute hemodialysis catheter) or active infection requiring antibiotic therapy at any time during the 2 weeks prior to screening. Tunneled hemodialysis catheters, and other "permanent" catheters are permitted. 8. Blood transfusion administered within 4 weeks prior to baseline. 9. Patients who received CSJ137 dose in the past. Other protocol-defined inclusion/exclusion criteria may apply.